ClinicalTrials.gg
TerminatedNCT05866926ADOREXTUpdated Mar 4, 2025Results posted

Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis

A Phase 3 interventional study of FAB122 in Amyotrophic Lateral Sclerosis, sponsored by Ferrer Internacional S.A.. Terminated at 1 site in Spain. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-03-04.

Sponsored by Ferrer Internacional S.A. · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
After the analysis of the main ADORE study it is concluded that there is no clinical benefit for the patients.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
201
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 56 studies in Amyotrophic Lateral Sclerosis with a site in Spain — 11 open to participants now, 16 under way, 5 of them phase 3. Amyotrophic Lateral Sclerosis · Spain.

Enrollment
27th of 51
201 · median 227
Started
2023
with 1 other
Phase 3
22 of 56
2 open now
Registered
43rd of 56
by date
Lead sponsor
2 of 56
Ferrer Internacional S.A.

Among the 56 studies in Amyotrophic Lateral Sclerosis with a site in Spain, this one is the 27th largest by enrollment of the 51 interventional ones that give a count, is one of 2 that started in 2023, is one of 22 in phase 3, and was the 43rd registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

11 of the 56 studies in Amyotrophic Lateral Sclerosis with a site in Spain are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Amyotrophic Lateral Sclerosis with a site in Spain, or all of them as a file.
02

Study summary

A multicenter, open-label extension study to investigate the long-term safety of FAB122 in patients with Amyotrophic Lateral Sclerosis

03

Conditions studied

  • Amyotrophic Lateral Sclerosis
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. who completed the full study period in the main ADORE study (FAB122-CT-2001);
  2. whom the investigator has no concern and judges tolerable for initiating or continuing treatment with FAB122 from a risk and benefit point of view;
  3. a female subject should not be able to become pregnant up to 30 days after the last dose of FAB122 and needs to meet at least one of the following criteria:

    • female who is of and has a negative pregnancy test at baseline and is non-lactating.
    • female subject who is not of reproductive potential is eligible without requiring the use of
  4. a male patient must:

    • agree he will not donate sperm during the period he will be using FAB122, AND use a condom during sexual intercourse with pregnant or non-pregnant women of

Exclusion criteria

Exclusion Criteria:

  1. Patient who has a medical condition or personal circumstances which, in the opinion of the investigator, will make initiation or continuation of treatment with FAB122 not tolerable for them from a risk and benefit point of view.
  2. Patient who discontinued study drug prematurely in the double-blind phase of the study (ADORE Study) for safety reasons.
  3. Patient who has received any other drug within the period between last visit of the main study and first visit of the extension study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
201 participants (actual)

Study arms

  • Experimental
    FAB122

    Drug: FAB122 Daily dose 100 mg Data presented for the FAB122 study group correspond to subjects receiving FAB122 in the ADORE study as well as the ADOREXT study (FAB122-FAB122).

    Drug: FAB122

  • Experimental
    Placebo

    Drug: FAB122 Daily dose 100 mg Data presented for the placebo study group correspond to subjects receiving placebo in the ADORE study and FAB122in the ADOREXT study (placebo-FAB122).

    Drug: FAB122

Interventions

  • DrugFAB122

    FAB122 Daily dose 100 mg

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Treatment Emergent Adverse Events

    To evaluate the long-term safety of FAB122 in patients with ALS by assessing Number of Participants experiencing Treatment Emergent Adverse Events, evaluating nature and severity. The study duration for these subjects, and therefore the duration of FAB122 treatment, was variable depending on the subject's start date, ranging from 3 to approximately 44 weeks.

    Time frame: approximately 44 weeks

Secondary outcomes

  1. The Secondary Efficacy Objective to Evaluate the Effect of Treatment With FAB122 Based on Change From Baseline in ALSFRS-R Until End of Study

    Change from baseline in ALSFRS-R total score until the end of the study. Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R), Maximum value is 48 points and represents better outcome. Minimum value is 0 and represents worse outcome.

    Time frame: 45 weeks

07

Results

Posted Mar 4, 2025

Participant flow

Participant flow — Overall Study
MilestoneFAB122Placebo
Started13566
Completed11054
Not completed2512
Withdrew: Death169
Withdrew: Lost to follow-up01
Withdrew: Adverse event10
Withdrew: Withdrawal by subject51
Withdrew: Disease progression10
Withdrew: Other causes21

Outcome measures

PrimaryNumber of Participants Experiencing Treatment Emergent Adverse Events

To evaluate the long-term safety of FAB122 in patients with ALS by assessing Number of Participants experiencing Treatment Emergent Adverse Events, evaluating nature and severity. The study duration for these subjects, and therefore the duration of FAB122 treatment, was variable depending on the subject's start date, ranging from 3 to approximately 44 weeks.

Time frame:
approximately 44 weeks
Reported as:
Number · Participants
Number of Participants Experiencing Treatment Emergent Adverse Events
ParticipantsFAB122Placebo
Any TEAE7741
Any Serious AE2915
Any Serious TEAE2915
Any TEAE leading to treatment discontinuation75
Any AE leading to death169
TEAE by relationship - Unrelated7540
TEAE by relationship - Related63
TEAE by Severity - Mild5231
TEAE by Severity - Moderate3217
TEAE by Severity - Severe2410
SecondaryThe Secondary Efficacy Objective to Evaluate the Effect of Treatment With FAB122 Based on Change From Baseline in ALSFRS-R Until End of Study

Change from baseline in ALSFRS-R total score until the end of the study. Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R), Maximum value is 48 points and represents better outcome. Minimum value is 0 and represents worse outcome.

Time frame:
45 weeks
Reported as:
Mean · units on a scale
The Secondary Efficacy Objective to Evaluate the Effect of Treatment With FAB122 Based on Change From Baseline in ALSFRS-R Until End of Study
units on a scaleFAB122Placebo
The Secondary Efficacy Objective to Evaluate the Effect of Treatment With FAB122 Based on Change From Baseline in ALSFRS-R Until End of Study-4.4 ± 4.8-3.8 ± 5

Adverse events

Collected over 45 weeks. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FAB12216/135 (11.9%)29/135 (21.5%)77/135 (57%)
Placebo9/66 (13.6%)15/66 (22.7%)41/66 (62.1%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventFAB122Placebo
Respiratory FailureRespiratory, thoracic and mediastinal disorders10/1354/66
DysponeaRespiratory, thoracic and mediastinal disorders2/1352/66
DeathGeneral disorders0/1352/66
PneumoniaInfections and infestations4/1351/66
Chronic respiratory failureRespiratory, thoracic and mediastinal disorders2/1351/66
Pneumonia aspirationInfections and infestations2/1351/66
COVID-19Infections and infestations1/1351/66
Lower respiratory track infectionInfections and infestations0/1351/66
Craniocerebral injuryInjury, poisoning and procedural complications0/1351/66
Amyotrophic Lateral SclerosisNervous system disorders0/1351/66
Most frequent other events
Showing 10 of 25
Most frequent other events
EventFAB122Placebo
FallInjury, poisoning and procedural complications5/1356/66
Urinary track infectiousInfections and infestations11/1351/66
Respiratory failureRespiratory, thoracic and mediastinal disorders11/1354/66
DysphagiaGastrointestinal disorders7/1353/66
DiarrhoeaGastrointestinal disorders1/1353/66
Renal ColicRenal and urinary disorders1/1353/66
PneumoniaInfections and infestations6/1351/66
Upper respiratory tract infectionInfections and infestations3/1352/66
InfluenzaInfections and infestations0/1352/66
Lower respiratory track infectionInfections and infestations0/1352/66

Baseline characteristics

Data presented for the FAB122 study group correspond to subjects receiving FAB122 in the ADORE study as well as in the ADOREXT study (FAB122-FAB122). Data presented for the Placebo study group correspond to subjects receiving Placebo in the ADORE study and FAB122 in the ADOREXT study (Placebo-FAB122).

Age, Customized
Age, Customized(years)FAB122PlaceboTotal
Mean (SD)58.4 ± 10.658.5 ± 10.558.5 ± 10.5
Sex: Female, Male
Sex: Female, Male(Participants)FAB122PlaceboTotal
Female573087
Male7836114
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)FAB122PlaceboTotal
Hispanic or Latino281644
Not Hispanic or Latino9448142
Unknown or Not Reported13215
Race (NIH/OMB)
Race (NIH/OMB)(Participants)FAB122PlaceboTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American000
White11963182
More than one race000
Unknown or Not Reported15318
Region of Enrollment
Region of Enrollment(participants)FAB122PlaceboTotal
Europe13566201
BMI
BMI(kg/m^2)FAB122PlaceboTotal
Mean25.64 ± 4.0324.76 ± 3.2325.35 ± 3.8
Weight
Weight(KG)FAB122PlaceboTotal
Mean74.87 ± 14.8371.07 ± 13.3273.62 ± 14.43
Height
Height(CM)FAB122PlaceboTotal
Mean170.5 ± 9.5169 ± 9.8170 ± 9.6
08

Study locations

1 site
  • Hospital Universitari de Bellvitge
    Barcelona, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2023 to primary completion in Jan 2024, 10 months.

Results were first posted in Mar 2025, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2023
First posted
May 19, 2023
StartActual
Mar 6, 2023
Primary completionActual
Jan 9, 2024
CompletionActual
Feb 22, 2024
Results first posted
Mar 4, 2025
Last update
Mar 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05866926
Responsible party
Sponsor
First posted
May 19, 2023
Start date
Mar 6, 2023
Primary completion
Jan 9, 2024
Completion
Feb 22, 2024
Results posted
Mar 4, 2025
Last update
Mar 4, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion